Repligen (NASDAQ:RGEN) Downgraded to Hold Rating by Wall Street Zen

Repligen (NASDAQ:RGEN) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also recently weighed in on the stock. UBS Group lowered their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday. Barclays reduced their price target on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company lowered their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.58.

Repligen Price Performance

Shares of RGEN opened at $128.73 on Friday. The firm has a market capitalization of $7.25 billion, a PE ratio of 151.45, a P/E/G ratio of 2.54 and a beta of 1.13. The stock’s 50 day moving average is $154.18 and its two-hundred day moving average is $146.80. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the business earned $0.44 earnings per share. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares in the company, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in RGEN. Measured Wealth Private Client Group LLC purchased a new position in Repligen during the third quarter worth about $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen during the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen during the 4th quarter worth about $36,000. Finally, Hantz Financial Services Inc. boosted its position in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.